Obesity and type 2 diabetes mellitus are major burdens in older adults; they affect > 40% and 29% of older adults, respectively, and are strongly associated with comorbidities such as cardiovascular disease.

GLP-1 receptor agonists, including semaglutide, tirzepatide, and liraglutide, are used in older adults, with a specific focus on improving metabolic health by enhancing weight loss, improving glycemic control, and protecting the cardiovascular system.

GLP-1 receptor agonists are a good option for the treatment of obesity and T2DM in older adults; nevertheless, in this population, it is important to consider the risk for sarcopenia, malnutrition, gastrointestinal side effects, and polypharmacy.